Novocure's Optune Pax approved in Japan for locally advanced pancreatic cancer
Japan's Ministry of Health, Labour and Welfare approved Optune Pax for adults with unresectable locally advanced pancreatic cancer, used with gemcitabine and nab-paclitaxel. The approval is based on the Phase 3 PANOVA-3 trial, which met its primary endpoint of statistically significant improvement in median overall survival, and it extends the device's regulatory approvals to another market.
Key points
- Approval was first announced in a September 15, 2026 press release; the October 1, 2026 exhibit repeats it.
- PANOVA-3 showed a statistically significant improvement in median overall survival for patients treated with TTFields.
- Optune Pax was previously approved by the U.S. FDA in February 2026 and received a CE Mark in June 2026.
- Device-related skin adverse events occurred in 76.3% of Optune Pax-treated participants; 21 (7.7%) had a Grade 3 or higher event.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.